WO2026139825 - AN ENGINEERED CELL COMPRISING AN ANTI-CD19 AND ANTI-CD20 CHIMERIC ANTIGEN RECEPTOR, A NUCLEIC ACID OR VECTOR, A KIT AND THEIR USE
National phase entry is expected:
Publication Number
WO/2026/139825
Publication Date
02.07.2026
International Application No.
PCT/IB2025/063221
International Filing Date
19.12.2025
Title **
[English]
AN ENGINEERED CELL COMPRISING AN ANTI-CD19 AND ANTI-CD20 CHIMERIC ANTIGEN RECEPTOR, A NUCLEIC ACID OR VECTOR, A KIT AND THEIR USE
[French]
CELLULE MODIFIÉE COMPRENANT UN RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE ANTI-CD19 ET ANTI-CD20, ACIDE NUCLÉIQUE OU VECTEUR, KIT ET LEUR UTILISATION
Applicants **
AVENCELL THERAPEUTICS INC.
Inventors
BOYERINAS, Ben
SPEHR, Johannes
ASHOURA, Norah
Priority Data
24223098.5
23.12.2024
EP
63/738,192
23.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2367 | |
| EPO | Filing, Examination, Granting | 10678 | |
| Japan | Filing, Examination, Granting | 2277 | |
| South Korea | Filing, Examination, Granting | 2373 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
23,635
Contact Us
Abstract[English]
The present invention relates to an engineered cell comprising at least one chimeric antigen receptor polypeptide specific for CD19 and CD20, a pharmaceutical composition comprising the engineered cell, a nucleic acid or vector comprising a nucleotide sequence encoding the chimeric antigen receptor polypeptide specific for CD19 and CD20 and a kit comprising the engineered cell, in particular for use in the treatment of cancer, infectious disease or autoimmune disease.[French]
La présente invention concerne une cellule modifiée comprenant au moins un polypeptide qui est un récepteur antigénique chimérique spécifique de CD19 et CD20, une composition pharmaceutique comprenant la cellule modifiée, un acide nucléique ou un vecteur comprenant une séquence nucléotidique codant pour le polypeptide formant le récepteur antigénique chimérique spécifique de CD19 et CD20 et un kit comprenant la cellule modifiée, en particulier pour une utilisation dans le traitement du cancer, d'une maladie infectieuse ou d'une maladie auto-immune.